Comparative Pharmacology
Head-to-head clinical analysis: BENADRYL versus DISOPHROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENADRYL versus DISOPHROL.
BENADRYL vs DISOPHROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine; inverse agonist at histamine H1 receptors, blocking histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction; also anticholinergic and sedative.
Disophrol is a combination of dexbrompheniramine, a first-generation antihistamine that blocks H1 receptors, and pseudoephedrine, a sympathomimetic amine that stimulates alpha-adrenergic receptors causing vasoconstriction.
25-50 mg orally every 4-6 hours as needed; maximum 300 mg per day. Alternatively, 10-50 mg intramuscularly or intravenously once, maximum 100 mg per dose (IV route preferred).
1 tablet (6 mg dexbrompheniramine maleate / 60 mg pseudoephedrine sulfate) orally every 4-6 hours; not to exceed 4 tablets in 24 hours.
None Documented
None Documented
Terminal elimination half-life 4-8 hours; prolonged in hepatic impairment (up to 20 hours).
Terminal elimination half-life is 3-4 hours in adults; in renal impairment, half-life may be prolonged up to 8-12 hours requiring dose adjustment.
Renal (90% as metabolites, <5% unchanged); minimal biliary/fecal.
Renal excretion of unchanged drug and metabolites; approximately 60-70% of a dose eliminated in urine as unchanged drug and glucuronide conjugates, with <10% in feces.
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination